Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy

Stanford Health Care

Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN Streiff, M. B., Holmstrom, B., Angelini, D., Ashrani, A., Buckner, T., Diep, R., Fertrin, K. Y., Fogerty, A. E., Crestani, N. G., Gangaraju, R., Rojas-Hernandez, C., Goldhaber, S. Z., Ibrahim, I., Kubal, T., Leavitt, A. D., Lim, M., Mann, J., Mantha, S., Morton, C., Nester, A., O'Brien, A., Ortel, T. L., Pine, A., Pishko, A., Ranade, M., Salmasi, A., Schaefer, J., Williams, E., Wool, G., Wun, T., Montgomery, S., Nguyen, J., Freedman-Cass, D., Sliker, B. 2024; 22 (7): 483-506

Abstract

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease provide strategies for the prevention, diagnosis, and treatment of venous thromboembolism (VTE) in adult patients with cancer. VTE is a common and life-threatening condition in patients with cancer, and its management often requires multidisciplinary efforts. The NCCN panel is comprised of specialists spanning various fields, including cardiology, hematology, medical oncology, internal medicine, interventional radiology, and pharmacology. The content featured in this issue specifically addresses the evaluation and recommended treatment options outlined in the NCCN Guidelines for the diverse subtypes of cancer-associated VTE.

View details for DOI 10.6004/jnccn.2024.0046

View details for PubMedID 39236759